Abstracts

964 – HIV Detection in Emergency Departments Through a Targeted Screening Protocol: The VIHGILA Project

Background Early diagnosis of undetected HIV infection is essential for controlling transmission and improving patient outcomes. Emergency departments (EDs) are critical access points for identifying hidden cases. Since 2021, the VIHGILA project, implemented in 25 hospitals in Catalonia (Spain), has aimed to proactively diagnose HIV infection across six clinical scenarios: suspected sexually transmitted infection (STI),…

965 – HIV Testing and Positivity Among STI-Tested Patients in 2 Urban Emergency Departments

Background Emergency departments (EDs) are key venues for HIV detection, especially among patients with sexually transmitted infections (STIs). While STI testing is common, HIV testing is inconsistent. We evaluated HIV testing, HIV positivity, and estimated missed infections among ED patients undergoing STI testing at two hospitals in a single health system. Methods We conducted a…

996 – Once-Yearly Lenacapavir for PrEP: Model-Informed Dose Determination and Phase III Trial Design

Background Twice-yearly subcutaneous lenacapavir (LEN) demonstrated high efficacy and favorable safety in two Phase 3 trials (PURPOSE 1 and 2) conducted in a diverse population of people who would benefit from pre-exposure prophylaxis (PWBP), facilitating approval in the US and EU. Extending the LEN dosing interval to once-yearly has the potential to further improve pre-exposure…

382 – HIV-Infected Cells Expressing Envelope Display Distinct Phenotypes in ART-Treated and Viremic PWH

Background HIV reservoirs persist despite antiretroviral therapy (ART) and remain a major barrier to cure. Defining the phenotype and host–virus interactions of reservoir cells is critical to guide eradication strategies. We developed Env-Flow to detect combined expression of capsid (p24/Gag) and envelope (Env) proteins in productively infected cells from viremic individuals and in reactivated reservoir…

246 – Clinical, Immune, and Neuro-Motor Profiles Linked to STING1 Gene Variants in People Living With HIV

Background Variants in the STING1/TMEM173 gene influence innate immune signaling. The HAQ haplotype (R71H, G230A, R293Q) and R232H, have been linked to reduced age-related comorbidities in general population and slower HIV progression. This pilot study aimed to investigate how STING1 variants affect immune control, comorbidities, and functional outcomes in People Living with HIV (PLWH). Methods…

285 – Rectal Microbiome Associations With HIV Vaccine-Induced Binding Antibody Responses in RV306

Background The rectal mucosa, a major portal for HIV-1 entry, harbors a microbial community that shapes local immune homeostasis and might influence systemic immune responses to vaccines. We investigated the bidirectional interactions between the rectal microbiome and vaccine-induced binding antibody (bAb) responses in the RV144 ALVAC-HIV / AIDSVAX® B/E prime/boost vaccine regimen given in the…

575 – Continuous Increase in HIV-1 Resistance to Neutralization by bNAbs Over the Past 30 Years

Background The efficacy of broadly neutralizing antibodies (bNAbs) is affected by the genetic diversity of HIV-1 and the ongoing escape from autologous neutralizing Abs at the population level. We investigated the current state of neutralization sensitivity of recent transmitted/founder (T/F) variants, with a focus on subtype B and CRF02_AG, the predominant clades in North America,…

578 – In Vivo Escape Pathways to VRC07-523LS and VRC01LS and Their Effects on CD4bs bNAb Susceptibility

Background Substantial inter- and intra-individual HIV diversity remains a major challenge in developing successful immune-based therapies. Despite the ability of broadly neutralizing antibodies (bNAbs) to neutralize genetically diverse strains, viral escape mutations can still emerge in vivo. To overcome this, it is essential to gain a deeper understanding of the in vivo evolution of HIV…